Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7423990
Reference Type
Journal Article
Title
The Contraceptive Vaginal Ring
Author(s)
Mandelbaum, RS; Shoupe, D; ,
Year
2020
Publisher
Springer International Publishing
Location
Cham
Book Title
The Handbook of Contraception
Page Numbers
73-96
DOI
10.1007/978-3-030-46391-5_5
URL
http://link.springer.com/10.1007/978-3-030-46391-5_5
Exit
Abstract
Contraceptive vaginal rings (CVR) are plastic polymer rings containing sex steroids that are directly absorbed through the vaginal epithelium into systemic circulation for highly effective contraception without the need for daily dosing. There are currently two CVRs that are FDA-approved for use in the United States. The ENG/EE ring (NuvaRing) contains etonogestrel (ENG) and ethinyl estradiol (EE) and was approved for use in the United States in 2001. It is the most widely used and studied CVR. The SA/EE ring (Annovera), which contains segesterone acetate (SA) and ethinyl estradiol (EE), was just approved by the FDA in 2018 and should be available within the next year. Both the ENG/EE and SA/EE rings are highly effective, similar to other combined hormonal methods, and have excellent cycle control. A third progesterone-only CVR, the Progering, is only available in Latin America for postpartum lactating women. This chapter primarily focuses on the ENG/EE ring but also includes currently available data on the SA/EE ring. Pharmacokinetics, mechanism of action, effectiveness, advantages and disadvantages, clinical use, and adverse effects of CVRs are addressed in this chapter.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity